



The FDA De Novo medical device pathway, 
patents and anticompetition
The interaction between patents and FDA’s De Novo and 510(k) regulatory pathways has the potential to threaten 
follow-on innovation for medical devices.
The US Food and Drug Administration (FDA) has long been criticized — perhaps unfairly — for failing to 
expeditiously approve groundbreaking 
medical devices. In the views of some, 
this has contributed to stagnation in the 
advancement of the medical device market 
and depressed competition among purveyors 
of new devices. The 21st Century Cures 
Act of 2016 has been lauded for attempting 
to tackle these problems by easing several 
pathways for regulatory allowance. But some 
of the agency’s recent guidances in the area 
may hinder competition by opening the 
gates to an anticompetitive patent strategy, 
one whereby marketers of De Novo medical 
devices — medical devices given their own 
‘device type’ category — can kettle follow-on 
applicants into patent infringement litigation. 
Knowing this, marketers of medical devices 
may avoid the 21st Century Cures Act’s 
expansion of the 510(k) pathway for  
De Novo device types, defeating one of  
the principal purposes of the act.
The FDA De Novo pathway
This anticompetitive patent strategy begins 
with how the 21st Century Cures Act governs 
De Novo medical devices. De Novo devices 
are those for which general and special 
“controls” provide a “reasonable assurance” 
of the device’s safety and effectiveness, 
even though there are no legally marketed 
devices of the same type1. These controls are 
basic requirements to ensure devices’ safety 
and efficacy in the real-world marketplace 
(for example, requirements pertaining to 
manufacturing practices) or, in the case of 
special controls, specific to the device type, 
such as performance standards; for instance, 
that external cardiac pacemakers should not 
deliver current at a pulse amplitude greater 
than 200 mA.
In general, special controls for De Novo 
devices present a problem to FDA because 
the requirements to ensure “safety and 
effectiveness” are difficult to know without 
extensive testing in the field. In one case, 
topical tissue adhesives — ‘liquid bandages’ 
— were found to need special controls a 
full decade after they were first introduced2. 
Those controls related to the heat degradation 
properties of such bandages; unexpectedly, 
heat from the skin degraded one component 
of the gel into formaldehyde. Because De 
Novo devices are, as the name suggests, 
new device types, problems such as these 
present the quandary of how to ascertain, 
with minimal historical comparisons, which 
special controls would be needed to ensure 
their safety and effectiveness.
In an attempt to cut this epistemic knot, 
FDA has recently finalized a regulatory 
guidance that asks De Novo applicants 
to propose for themselves their devices’ 
respective special controls3. Such proposals 
must come with explanations for why such 
controls “provide a reasonable assurance of 
safety and effectiveness” and can include 
a wide variety of factors, including those 
related to devices’ usability, biocompatibility, 
and stability over time. In addition, these 
special controls (some of which are also 
classified as “performance standards”) may 
cover a device type’s core “technological 
characteristics,” its “materials, design, energy 
source, and other device features”4.
These controls are critical for the 510(k) 
pathway — the pathway by which over 96% of 
new devices are reviewed by the agency5. The 
interest in the 510(k) pathway stems from its 
leniency: rather than mandating clinical trials, 
510(k) devices are cleared by FDA, typically 
within 90 days, if their manufacturers can 
show “substantial equivalence” to a “predicate 
device.” This determination requires a 
number of steps, but two are of importance 
here. A 510(k) device must endeavor to show 
that it possesses the same “technological 
characteristics” as the predicate device. If it 
fails to do so, the applicant must then instead 
show that the follow-on device does not 
raise any “different questions of safety and 
effectiveness”3. Failing this, the device is “not 
substantially equivalent” to the predicate and 
therefore cannot be marketed6.
Patents covering De Novo devices’ 
technological characteristics and 
controls
The combination of these guidances and 
the 21st Century Cures Act establishes a 
potentially anticompetitive patent strategy. 
De Novo applicants may patent the core 
technological characteristics of their devices, 
essential for FDA’s determination that 
the follow-on application is “substantially 
equivalent.” In addition, the De Novo 
applicant can advocate before the agency 
that its “performance standards” are, in 
fact, core technological characteristics for 
the device’s “special controls.” As a result, a 
follow-on applicant is given a fatal choice: 
it must either admit that it uses the same 
technological characteristics as the patented, 
predicate device — essentially, an admission 
of patent infringement — or that it uses 
different technological characteristics, 
which is an admission that the device is not 
substantially equivalent to the predicate. 
In short: patenting core technological 
characteristics of a De Novo device and 
tying performance standards to these 
underlying technological characteristics 
gives follow-on developers an impossible 
path toward entry.
While this anticompetitive strategy is 
a nascent worry, it is decidedly real. Take, 
for example, the t:slim X2 Insulin Pump, 
marketed by Tandem Diabetes Care, 
classified as a De Novo device in 2019 (ref. 7). 
Its special controls include “[e]lectrical 
safety, electromagnetic compatibility, and 
radio frequency wireless safety testing,” 
including the “[s]haring of necessary state 
information between the pump and any 
digitally connected alternate controllers” 
— controls that overlap the device’s core 
technological characteristics. But these 
very characteristics have been patented by 
Tandem Diabetes Care8. A potential 510(k) 
application using the t:slim X2 Insulin Pump 
as a predicate would therefore be faced with 
either admitting to the FDA that it either 
uses the same technological characteristics 
as the pump, and likely infringes Tandem’s 
patents, or that it fails to match the pump’s 
performance standards — an admission that 
its 510(k) should not be approved.
The Bose Hearing Aid presents another 
example of patents covering De Novo 
devices’ special controls. The hearing 
aid — specifically typed as a “self-fitting 
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air-conduction hearing aid” — uses active 
noise reduction technology, a feature 
designed to “reduce environmental noise 
and to decrease amplification of the user’s 
own voice typical of an occluding earbud”9. 
This includes directional sensitivity, the 
ability of the hearing aids’ microphones to 
detect the presence of louder-than-room 
sound in only one ear’s hearing aid. This 
makes the Bose Hearing Aid’s directional 
sensitivity a core feature of the device’s 
“electroacoustic parameters,” one of its 
special controls. But this directional 
sensitivity is precisely what is claimed 
in Bose’s US Patent 10,623,870, making 
follow-on applicants interested in making 
their own active noise reduction hearing aid 
targets for claims of patent infringement. 
This is potentially concerning given the 
quantity of patent litigation clouding the 
hearing aid market10–12.
NeuroSigma’s transcutaneous electrical 
nerve stimulator for attention deficit 
hyperactivity disorder, the Monarch eTNS 
System, similarly lists specific electrical 
stimulation parameters as special controls13. 
But the company has at least ten patents 
covering various aspects of its De Novo 
device, including US Patent 10,195,435, 
which claims the same ranges of frequency, 
pulse duration, output current density and 
charge density as the Monarch eTNS. Any 
510(k) applicants seeking to use these same 
parameters for their own ADHD stimulators 
— as they would be required under FDA’s 
recent guidances — would make themselves 
ripe for claims of patent infringement.
Examples such as these are likely to 
become commonplace. In the three years 
since the act was signed into law, FDA has 
approved 97 De Novo devices — roughly 30 
a year — in contrast to an average of about 
9 devices in years prior. In addition, many 
medical devices are becoming increasingly 
complex such that controls on elements 
like energy sources and software — core 
technological characteristics — are the 
difference between devices being safe 
and effective and them being dangerous 
contraptions14. These developments are 
likely to increase an already high baseline 
level of patent litigation for medical devices 
— 6% of the roughly 4,500 patent cases filed 
each year, more than cases pertaining to 
telecommunications, chemicals or cars15.
In addition, the relationship between 
devices’ special controls and patents covering 
them has the potential to affect diagnostic 
testing for diseases, such as COVID-19. 
Because many diagnostic tests are legally 
considered to be medical devices in FDA’s 
purview, one of the more popular avenues 
for approval for diagnostic tests is the  
De Novo pathway. Indeed, approved  
De Novo devices already include test kits 
for Zika16, Ebola17 and West Nile18 viruses, 
among others. Unsurprisingly, such kits are 
subject to robust special and performance 
controls to ensure their clinical and analytic  
validity, controls that can rarely be sidestepped 
by follow-on applicants. If the providers of 
such devices patent these controls, 510(k) 
applicants would be effectively blocked from 
offering competing devices. While this is 
currently less of a concern for COVID-19 
test kits because of the way in which they 
have been authorized by FDA — under an 
Emergency Use Authorization pathway, with 
less stringent controls — patents covering 
the kits’ special controls may well take an 
anticompetitive bent once the pandemic 
begins to subside and the agency starts to 
require preapproval applications such as 
those from the De Novo pathway.
conclusions
The interaction between patents and FDA’s 
De Novo FDA 501(k) pathways present an 
opportunity for regulatory gamesmanship 
that potentially detracts from a history of 
robust development in the medical device 
space. Unlike approval of drugs, regulatory 
approval of medical devices is not tied to a 
prior resolution of patent infringement. This 
has, since the Medical Device Amendments 
of 1976, allowed the robust and competitive 
development of the medical device market, 
including the opportunity to garner 
real-world evidence of devices’ safety and 
effectiveness; follow-on applicants could 
negotiate for patent licenses after approval. 
And while the 510(k) pathway has come 
under some recent criticism19, the fact 
remains that the vast bulk of medical devices 
in the United States enter the market this 
way. The medical device market largely 
turns on how the 510(k) process is governed.
FDA’s guidances on special controls are 
an admirable step in the right direction. But 
the agency should be aware of how De Novo 
applicants establishing their own controls — 
where applicants’ interests may be aligned to 
thwart competition — are problematic. Foxes 
tend not to be good stewards of henhouses. 
FDA should clarify its guidances to note that 
it will review — and vigorously so — whether 
De Novo applicants’ specific special controls 
employed are necessary for the device’s safety 
and efficacy and whether they overlap with 
the core technological characteristics of the 
device itself. FDA could also ask De Novo 
applicants whether any proposed, novel 
special controls could be otherwise satisfied 
using industry standards, which tend to 
be less prone to patent blocking. And, in 
general, better oversight of performance 
standards for De Novo devices from FDA is 
needed. Policing such behavior would ensure 
that the 21st Century Cures Act continues 
the advance of competition in the medical 
device marketplace.
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